What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?

Simply Wall St.01-10

In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602581249?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-10 15:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602581249","market":"sg","top_or_hot":-1,"title":"What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?","media":"Simply Wall St.","content":"<div>\n<p>In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio","article_id":"2602581249","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602581249","pubTimestamp":1768029368,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments in institutional holdings. \nAt the same time, multiple brokerage firms reiterated positive views on Twist Bioscience’s semiconductor-based DNA synthesis platform, collectively maintaining an “Outperform” stance backed by confidence in its synthetic biology technology. \nBuilding on this renewed...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","TWST":"Twist Bioscience Corp","DNA":"Ginkgo Bioworks Holdings Inc.","BK4109":"特种化学制品","BK4588":"碎股","BK4121":"生命科学工具和服务"},"translate_title":"首席执行官薪酬和内幕交易揭示了Twist Bioscience(TWST)合成DNA雄心的哪些方面？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA":1.5,"TWST":1.5},"content_text":"In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments in institutional holdings.  At the same time, multiple brokerage firms reiterated positive views on Twist Bioscience’s semiconductor-based DNA synthesis platform, collectively maintaining an “Outperform” stance backed by confidence in its synthetic biology technology.  Building on this renewed analyst optimism around Twist Bioscience’s DNA platform, we’ll now consider how it reshapes the company’s investment narrative. These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.AdvertisementTwist Bioscience Investment Narrative RecapTo own Twist Bioscience, you need to believe that its semiconductor-based DNA synthesis platform can translate into a durable, high-margin business despite continued losses and customer concentration. The recent jump in CEO compensation and insider selling does not materially change the key near term catalyst, which remains progress toward adjusted EBITDA breakeven, or the biggest risk, which is the potential need for future capital if losses persist. Among recent announcements, Twist’s Q4 2025 results and full year revenue of US$376.57 million, alongside a net loss of US$77.67 million, are most relevant here, because they frame how quickly the business might scale toward profitability. These figures sit in the background as analysts reiterate positive views on the company’s DNA platform, sharpening the contrast between technology enthusiasm and the ongoing earnings drag. Yet beneath the excitement around the DNA platform, investors should also be aware that... Read the full narrative on Twist Bioscience (it's free!)Twist Bioscience's narrative projects $575.2 million revenue and $92.4 million earnings by 2028. This requires 16.7% yearly revenue growth and a $177.6 million earnings increase from -$85.2 million today.Uncover how Twist Bioscience's forecasts yield a $35.62 fair value, in line with its current price.Exploring Other PerspectivesTWST 1-Year Stock Price Chart Three fair value estimates from the Simply Wall St Community cluster between US$35.47 and US$42, highlighting how differently private investors assess Twist’s potential. You can set these views against the company’s continued losses and the risk of a future capital raise, then decide which assumptions about Twist’s path to breakeven feel most realistic to you.Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth just $35.47!Build Your Own Twist Bioscience NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Twist Bioscience research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.Ready For A Different Approach?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 39 companies in the world exploring or producing it. Find the list for free.We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Twist Bioscience might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602581249","isCrawlerRequest":true}